Monsanto Roundup lawsuit payouts mean money for people who blame glyphosate-based Roundup, a weedkiller, for non-Hodgkin lymphoma, a lymph-system cancer. Payouts fall into closed 2020 deals and a proposed 2026 class deal that pays by exposure, disease type, and age. Bayer said its 2020 agreements paid $10.1-$10.9 billion for about 125,000 claims Bayer's June 2020 announcement. The Associated Press reports a $7.25 billion proposal for current and future failure-to-warn claims Associated Press report via SRN News.
Official resources:
- Register through Iastate’s official page — Use this page to review requirements and register directly.
- Read the official guidance from Epa — Use this primary source to verify the official guidance.
Table of Contents
- What the 2020 payouts covered
- How much the 2026 proposal would pay
- Who qualifies for a payment
- When would money arrive
- Why some claims could fail
What the 2020 payouts covered
Bayer said the June 2020 agreements would substantially resolve then-current Roundup litigation. The deals covered filed and unfiled claims alleging non-Hodgkin lymphoma.
Substantially resolve did not end all claims. Later plaintiffs pursued new failure-to-warn suits that led to the 2026 proposal.
How much the 2026 proposal would pay
The New Lede reports average awards range from about $10,000 to $165,000 under the proposal The New Lede's February 2026 report. An occupational user diagnosed under age 60 with aggressive NHL averages $165,000.
That average can move from 80% to 120% based on individual factors. Louisiana First News explains that people with proven exposure below 16 hours or 10 lifetime days would receive $150. It also notes faster or extraordinary payment for severe, heavy-home-use or hardship cases.
Who qualifies for a payment
The New Lede reports the proposal covers only non-Hodgkin lymphoma, not other cancers. It applies to people who purchased or applied glyphosate-based Roundup.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Low-exposure claimants still qualify for a small fixed sum. Keep work logs, purchase receipts, and medical records that show product, time, and diagnosis.
- non-Hodgkin lymphoma diagnosis, not another cancer
- purchase or application of glyphosate-based Roundup
- exposure amount, lymphoma type, and age at diagnosis set the tier
When would money arrive
BRELaw analysis of the Missouri ruling says the court gave preliminary approval in March 2026. The plan would pay in capped annual installments over up to 21 years.
Preliminary approval means the court allowed notice to move forward. BRELaw notes final approval remains pending and Bayer requires participation by the vast majority of claimants.
Why some claims could fail
Iowa State Center for Agricultural Law and Taxation explains the June 25, 2026 decision in Monsanto v. Durnell was 7-2 Iowa State analysis. The Court held federal pesticide law preempts state failure-to-warn claims where EPA registered the product without a cancer warning.
The decision reversed a $1.25M verdict. EPA concluded after review that glyphosate has no human-health risks of concern when used per label and is not a carcinogen. WHO's IARC classified glyphosate in March 2015 as probably carcinogenic to humans.
You Might Also Like
- Monsanto Roundup Lawsuit Settlement Payout Update for October 2026
- Depo-Provera Lawsuit Settlement Update: What Changed This Month?
- Pharmaceutical Lawsuit Settlement Guide 2026: Eligibility, Evidence, and Deadlines